Firefly Neuroscience's AI System Discovers Novel PTSD Biomarker
AIFF has more than doubled off its 52-week low of $0.618.
Summary
Firefly Neuroscience announced the discovery of a novel electrophysiological biomarker for Post-Traumatic Stress Disorder (PTSD) using its AI-driven Evoke System. This breakthrough is tied to the company's public-private partnership with the U.S. Department of War and leverages its extensive brain scan database. The identification of this biomarker could open significant commercial pathways, including expanding government engagement, serving as an objective endpoint in pharmaceutical trials, and informing clinical psychiatry. This scientific validation is a crucial positive development for the company, which has recently issued going concern warnings and relied on highly dilutive private placements to fund operations.
At the time of this announcement, AIFF was trading at $1.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $26.6M. The 52-week trading range was $0.62 to $3.77. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.